Radiation immunomodulatory gene tumor therapy of rats with intracerebral glioma tumors

Radiation Research

Volumn 173, Issue 4, 2010, Pages 433-440

  Persson, Bertil R R ^a   Koch, Catrin Baurus ^a   Grafstrm, Gustav ^a   Ceberg, Crister ^a   Rosenschld, Per Munckaf ^a   Nittby, Henrietta ^a   Widegren, Bengt ^a   Salford, Leif G ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COBALT 60; GAMMA INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CONTROLLED STUDY; FEMALE; GAMMA RADIATION; GENETIC TRANSFECTION; GLIOBLASTOMA; IMMUNIZATION; INOCULATION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION IMMUNOMODULATORY GENE TUMOR THERAPY; RAT; SURVIVAL TIME; TREATMENT RESPONSE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GENE THERAPY; GLIOMA; IMMUNOMODULATION; INJECTIONS, INTRAPERITONEAL; INTERFERON-GAMMA; MALE; RADIOTHERAPY DOSAGE; RATS; RATS, INBRED F344; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

RATTUS;

EID: 77950289842     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR1733.1     Document Type: Article

References (45)

1. J. S. Barnholtz-Sloan, A. E. Sloan and A. G. Schwartz, Cancer of the brain and other central nervous system. In SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001. Patient and Tumor Characteristics (L. A. Gloeckler Ries, J. L. Young, Jr., G. E. Keel, M. P. Eisner, Y. D. Lin and and M-J. D. Horner, Eds.), pp. 203-216. National Cancer Institute, Bethesda, MD, 2007.
2. R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. B. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi and R. O. Mirimanoff, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
3. J. Capala, B. H. Stenstam, K. S. Sköld, P. Munck af Rosenschöld, V. Giusti, C. Persson, E. Wallin, A. Brun, L. Franzén and R. Henriksson, Boron neutron capture therapy for glioblastoma multiforme: clinical studies in Sweden. J. Neurooncol. 62, 135-144 (2003).
4. R. Henriksson, J. Capala, A. Michanek, S-A. Lindahl, L. G. Salford, L. Franzén, E. Blomquist, J-E. Westlin and A. T. Bergenheim, Boron neutron capture therapy (BNCT) for glioblastoma multiforme: A phase II study evaluating a prolonged high-dose of boronophenylalanine. Radiother. Oncol. 88, 183-191 (2008).
5. L. Zhang, J. R. Conejo-Garcia, D. Katsaros, P. A. Gimotty, M. Massobrio, G. Regnani, A. Makrigiannakis, H. Gray, K. Schlienger and G. Coukos, Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203-213 (2003).
6. z T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinico-pathologic demonstration of antitumor immunity. Cancer Res. 61, 5132-5136 (2001).
7. z tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum. Pathol. 35, 808-816 (2004).
8. G. Shankar and M. L. Salgaller, Immune monitoring of cancer patients undergoing experimental immunotherapy. Curr. Opin. Mol. Therapeut. 2, 66-73 (2000).
9. A. Allione, M. Consalvo, P. Nanni, P. L. Lollini, F. Cavallo, M. Giovarelli, M. Forni, A. Gulino, M. P. Colombo and G. Forni, Immunizing and curative potential of replicating and non-replicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor-necrosis-factor-alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res. 54, 6022-6026 (1994).
10. R. E. Merchant, A. J. Grant, L. H. Merchant and H. F. Young, Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine-activated killer cells and recombinant interleukin-2. Cancer 62, 665-671 (1988).
11. R. E. Merchant, D. W. McVicar, L. H. Merchant and H. F. Young, Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial. J. Neurooncol.12, 75-83 (1992).
12. R. E. Merchant, L. H. Merchant, S. H. Cook, D. W. McVicar and H. F. Young, Intralesional infusion of lymphokine-activated killer (LAK) cell and recombinant interleukin-2 (RIL-2) for the treatment of patients with malignant brain tumour. Neurosurgery 23, 725-732 (1988).
13. R. E. Merchant, N. G. Baldwin, C. D. Rice and H. D. Bear, Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes. Neurol. Res. 19, 145-152 (1997).
14. E. Visse, P. Siesjö, B. Widegren and H. O. Sjögren, Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-c, interleukin-7, or B7-1-trans-fected tumor cells. Cancer Gene Ther. 6, 37-44 (1999).
15. P. Siesjö, E. Visse, M. Lindvall, L. Salford and H. O. Sjögren, Immunization with mutagen-treated (tum-) cells causes rejection of nonimmunogenic rat glioma isografts. Cancer Immunol. Immunother. 37, 67-74 (1993).
16. E. Visse, A. C. M. Johansson, B. Widegren, H. O. Sjögren and P. Siesjö, Immunohistochemical analysis of glioma-infiltrating leucocytes after peripheral therapeutic immunization with interferon-gamma-transfected glioma cells. Cancer Immunol. Immunother. 49, 142-151 (2000).
17. C. Bauréus-Koch, G. Nyberg, B. Widegren, L. G. Salford and B. R. R. Persson, Radiation sterilisation of cultured human brain tumour cells for clinical immune tumour therapy. Br. J. Cancer 90, 48-54 (2004).
18. A. Persson, G. Skagerberg, L. G. Salford and E. Englund, Immunotreatment in patients with glioblastoma multiforme-a histopathological evaluation of reactive and inflammatory changes. Clin. Neuropathol. 24, 201-208 (2005).
19. T. Roszman, L. Elliot and W. Brooks, Modulation of T-cell function by gliomas. Immunol. Today 12, 370-374 (1991).
20. M. R. Graf, J. T. Sauer and R. E. Merchant, Tumor infiltration by myeloid suppressor cells in response to T cell activation in rat gliomas. J. Neurooncol. 73, 29-36 (2005).
21. R. M. Prins, M. R. Graf and R. E. Merchant, Cytotoxic T cells infiltrating a glioma express an aberrant phenotype that is associated with decreased function and apoptosis. Cancer Immunol. Immunother. 50, 285-292 (2001).
22. M. Chakraborty, S. I. Abrams, C. N. Coleman, K. Camphausen, J. Schlom and J. W. Hodge, External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 64, 4328-4337 (2004).
23. J. L. Gulley, P. M. Arlen, A. Bastian, S. Morin, J. Marte, P. Beetham, K. Y. Tsang, J. Yokokawa, J. W. Hodge and W. Dahut, Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin. Cancer Res. 11, 3353-3362 (2005).
24. H. J. Sharp, E. K. Wansley, C. T. Garnett, M. Chakraborty, K. Camphausen, J. Schlom and J. W. Hodge, Synergistic antitumor activity of immune strategies combined with radiation. Front. Biosci. 12, 4900-4910 (2007).
25. E. W. Newcomb, S. Demaria, Y. Lukyanov, Y. Z. Shao, T. Schnee, N. Kawashima, L. Lan, J. K. Dewyngaert, D. Zagzag and S. C. Formenti, The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin. Cancer Res. 12, 4730-4737 (2006).
26. M. R. Graf, R. M. Prins, W. T. Hawkins and R. E. Merchant, Irradiated tumor cell vaccine for treatment of an established glioma. I. Successful treatment with combined radiotherapy and cellular vaccination. Cancer Immunol. Immunother. 51, 179-189 (2002).
27. K. Lumniczky, S. Desaknai, L. Mangel, B. Szende, H. Hamada, E. J. Hidvegi and G. Safrany, Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model. Cancer Gene Ther. 9, 44-52 (2002).
28. D. S. Gridley, J. Li, E. H. Kajioka, M. L. Andres, M. F. Moyers and J. M. Slater, Combination of pGL1-TNF-alpha gene and radiation (proton and gamma-ray) therapy against brain tumor. Anticancer Res. 20, 4195-4203 (2000).
29. J. Li, M. L. Andres, I. Fodor, G. A. Nelson and D. S. Gridley, Evaluation of pGL1-TNF-alpha therapy in combination with radiation. Oncol. Res. 10, 379-387 (1998).
30. H. J. Mauceri, N. N. Hanna, M. A. Beckett, D. H. Gorski, M. J. Staba, K. A. Stellato, K. Bigelow, R. Heimann, S. Gately and R. R. Weichselbaum, Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394, 287-291 (1998).
31. H. J. Mauceri, N. N. Hanna, M. J. Staba, M. A. Beckett, D. W. Kufe and R. R. Weichselbaum, Radiation-inducible gene therapy. Compt. Rend. Acad. Sci. Ser. III Sci. Vie Life Sci. 322, 225-228 (1999).
32. M. J. Staba, H. J. Mauceri, D. W. Kufe, D. E. Hallahan and R. R. Weichselbaum, Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther. 5, 293-300 (1998).
33. R. M. Prins, G. P. Scott, R. E. Merchant and M. R. Graf, Irradiated tumor cell vaccine for treatment of an established glioma. II. Expansion of myeloid suppressor cells that promote tumor progression. Cancer Immunol. Immunother. 51, 190-199 (2002).
34. C. T. Garnett, C. Palena, M. Chakraborty, K. Y. Tsang, J. Schlom and J. W. Hodge, Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 64, 7985-7994 (2004).
35. J. D. Bradley, Y. Kataoka, S. Advani, S. M. Chung, R. B. Arani, G. Y. Gillespie, R. J. Whitley, J. M. Markert, B. Roizman and R. R. Weichselbaum, Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin. Cancer Res. 5, 1517-1522 (1999).
36. M. Chakraborty, S. I. Abrams, K. Camphausen, K. B. Liu, T. Scott, C. N. Coleman and J. W. Hodge, Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J. Immunol. 170, 6338-6347 (2003).
37. E. J. Friedman, Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr. Pharm. Des. 8, 1765-1780 (2002).
38. E. C. Laiakis, J. E. Baulch and W. F. Morgan, Cytokine and chemokine responses after exposure to ionizing radiation: Implications for the astronauts. Adv. Space Res. 39, 1019-1025 (2007).
39. K. Shiraishi, Y. Ishiwata, K. Nakagawa, S. Yokochi, C. Taruki, T. Akuta, K. Ohtomo, K. Matsushima, T. Tamatani and S. Kanegasaki, Enhancement of antitumor radiation efficacy and consistent induction of the abscopal effect in mice by ECI301, an active variant of macrophage inflammatory protein-1 alpha. Clin. Cancer Res. 14, 1159-1166 (2008).
40. I. Marigo, L. Dolcetti, P. Serafini, P. Zanovello and V. Bronte, Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222, 162-179 (2008).
41. C. Belka, H. Ottinger, E. Kreuzfelder, M. Weinmann, M. Lindemann, A. Lepple-Wienhues, W. Budach, H. Grosse-Wilde and M. Bamberg, Impact of localized radiotherapy on blood immune cells counts and function in humans. Radiother. Oncol. 50, 199-204 (1999).
42. M. Tisch, F. Heimlich, V. Daniel, G. Opelz and H. Maier, Cellular immune defect caused by postsurgical radiation therapy in patients with head and neck cancer. Otolaryngol. Head Neck Surg. 119, 412-417 (1998).
43. J. J. Nemunaitis, R. O. Dillman, P. Schwarzenberger, N. Senzer, A. Tong, E. Devol, T. Chamberlin, D. Shawler and H. Fakhrai, Phase II study of a TGF-beta 2 antisense gene modified allogeneic tumor cell vaccine (Lucanix) in advanced NSCLC. J. Clin. Oncol. 24, 368S-368S (2006).
44. J. Nemunaitis, R. O. Dillman, P. O. Schwarzenberger, N. Senzer, C. Cunningham, J. Cutler, A. Tong, P. Kumar, B. Pappen and H Fakhrai, Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 24, 4721-4730 (2006).
45. H. Fakhrai, J. C. Mantil, L. Liu, G. L. Nicholson, C. S. Murphy-Satter, J. Ruppert and D. L. Shawler, Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther. 13, 1052-1060 (2006).